The Comprehensive Cohort Model In Effect of Vitamin D Supplementation On Insulin Resistance In Diabetic Type 2 Patients (A randomized controlled group beside the preference group).

The Comprehensive Cohort Model In Effect of Vitamin D Supplementation On Insulin Resistance In Diabetic Type 2 Patients(A randomized controlled group beside the preference group).

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201202219097N1

Enrollment

120

Registered

2012-12-24

Start date

2012-06-30

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Diabetes mellitus

Interventions

Intervention 1: Intervention group (in randomized group): Vitamin D, 50,000 IU tablets, orally, once a week for three months. Intervention 2: In control group (randomized group): Placebo of vitamin D,

Treatment - Drugs

Placebo

Intervention group (in randomized group): Vitamin D, 50,000 IU tablets, orally, once a week for three months

In control group (randomized group): Placebo of vitamin D, orally, once a week for three months

In intervention group (preference group): Vitamin D, 50,000 IU orally, once a week for three months

In control group (preference group ): No Action

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Catching type 2 diabetes confirmed by blood tests and proven by the endocrinologist. Fasting blood glucose concentration should be less than 400 mg / dl. 30-70 years of age. Exclusion criteria: The consumption of vitamin D supplements, calcium or omega-3 (n23) during the past 3 months. Patients who have changed blood glucose lowering drugs (from pills to insulin) during the study. Catching any concurrent clinical disease that can affect the metabolism of vitamin D, such as kidney disease, liver disease, other endocrine disorders, and malignancies.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting insulin. Timepoint: Before the intervention, three months after the intervention. Method of measurement: Eliza's method.;Insulin resistance. Timepoint: Before the intervention, three months after the intervention. Method of measurement: Measured by fasting insulin and glucose, and then their sum is divided by 22.5.;Fasting glucose. Timepoint: Before the intervention, three months after the intervention. Method of measurement: Eliza's method.	—

Measure

Time frame

Fasting insulin. Timepoint: Before the intervention, three months after the intervention. Method of measurement: Eliza's method.;Insulin resistance. Timepoint: Before the intervention, three months after the intervention. Method of measurement: Measured by fasting insulin and glucose, and then their sum is divided by 22.5.;Fasting glucose. Timepoint: Before the intervention, three months after the intervention. Method of measurement: Eliza's method.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMostafa Vahedian

Isfahan University of Medical Sciences

mvahedian@muq.ac.ir+98 25 1612 2150

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026